入组标准导致黑人胰腺癌患者临床试验入组与参与差异持续存在
研究基于2010至2019年弗吉尼亚联邦大学健康中心676例胰腺导管腺癌患者,比较传统临床试验入组标准对黑人与白人患者合格性的影响。黑人患者因传统标准不合格比例高于白人(42.4% vs 33.2%,P=.023),主要归因于低白蛋白血症、HIV、乙型肝炎和丙型肝炎。策略性修订标准后两组不合格率趋于均衡(26.8% vs 24.8%,P=.581)。
要点
- 传统入组标准下黑人患者不合格率42.4%,高于白人33.2%(P=.023)。
- 差异主要源于低白蛋白血症、HIV、乙肝和丙肝的排除。
- 修订标准后黑人26.8% vs 白人24.8%不合格(P=.581)。
核心结论
- 传统入组标准差异化排除黑人患者参与胰腺导管腺癌临床试验,持续造成差异并限制普适性,且常缺乏医学正当性。
- 修订标准可能改善参与者多样性,而不损害安全性或研究结果。
研究设计与样本
- 从ClinicalTrials.gov获取传统胰腺导管腺癌试验入组标准。
- 纳入2010至2019年在弗吉尼亚联邦大学健康中心就诊的胰腺导管腺癌患者,共676例。
- 临床数据来自计费代码和电子病历中的离散值。
- 使用卡方检验和非条件最大似然比法比值比确定种族组间入组标准差异。
主要发现
- 676例患者中,多数为黑人(42.5%)或白人(51.6%)。
- 传统标准下黑人患者不合格比例高于白人(42.4% vs 33.2%,P=.023)。
- 不合格差异归因于低白蛋白血症(14.1% vs 7.9%,P=.023)、HIV(3.1% vs 0.3%,P=.010)、乙型肝炎(1.7% vs 0%,P=.043)和丙型肝炎(9.1% vs 3.4%,P=.005)。
- 黑人患者因肾功能不全、近期冠状动脉支架置入和未控制糖尿病而不合格的可能性在数值上更高。
- 既往癌症治疗排除的黑人患者少于白人(9.1% vs 14.0%,P=.072),主要归因于接受新辅助化疗的比例较低。
临床怎么用
- 作者认为,修订入组标准可能在不损害安全性或研究结果的前提下改善参与者多样性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Clinical trials determine safety and efficacy of cancer therapeutics and establish standards of care. Minority patient participation in cancer clinical trials is dismal. We aimed to determine the impact of eligibility criteria on disparities in pancreatic ductal adenocarcinoma (PDAC) clinical trial candidacy. METHODS: Traditional PDAC trial eligibility criteria were obtained from ClinicalTrials.gov. Patients with PDAC who sought care at Virginia Commonwealth University Health from 2010 to 2019 were included. Clinical data were obtained from billing codes and discrete values in the electronic medical record. Eligibility criteria differences between racial groups were determined using chi-squared tests and unconditional maximum likelihood-based odds ratios. RESULTS: Among 676 patients, most identified as Black or White race (42.5% and 51.6%, respectively). Using traditional criteria, Black patients were more likely to be ineligible for participation compared with White patients (42.4% v 33.2%, P = .023) secondary to hypoalbuminemia (14.1% v 7.9%, P = .023), HIV (3.1% v 0.3%, P = .010), hepatitis B (1.7% v 0%, P = .043), and hepatitis C (9.1% v 3.4%, P = .005). Black patients were also numerically more likely to be ineligible because of renal dysfunction, recent coronary stenting, and uncontrolled diabetes mellitus. Prior cancer treatment excluded fewer Black than White patients (9.1% v 14.0%, P = .072), most attributable to lower rates of neoadjuvant chemotherapy received. Strategic eligibility criteria revisions could equalize ineligibility rates between Black and White patients (26.8% v 24.8%, P = .581). CONCLUSION: Traditional eligibility criteria differentially exclude Black patients from participating in PDAC clinical trials. These criteria perpetuate disparities, limit generalizability, and are often not medically justifiable. Revised criteria may improve participant diversity, without compromising safety or study results.
引用
- Riner AN, Girma S, Vudatha V, et al. Eligibility Criteria Perpetuate Disparities in Enrollment and Participation of Black Patients in Pancreatic Cancer Clinical Trials. J Clin Oncol. 2022. PMID: 35316089. doi:10.1200/JCO.21.02492
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。